Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials

By sjmartinez • October 30, 2023

Cheema HA, Shafiee A, Athar MMT, Rafiei MA, Mehmannavaz A, Jafarabady K, Shahid A, Ahmad A, Ijaz SH, Dani SS, Minhas AMK, Nashwan AJ, Fudim M, Fonarow GC. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2023 Oct 12;10:1273781. doi: 10.3389/fcvm.2023.1273781. PMID: 37900570; PMCID: PMC10602781.

Tags: Cardiology/Epi, dapagliflozin, empagliflozin, heart failure, HFPEF, Publications, SGLT2I

Related Posts

The Cardiovascular Care of the Pediatric Athlete

Dean PN, Brothers JA, Burns K, Edelson JB, Etheridge S, Phelan DM, Shafer K, Snyder C, Molossi S, Danielian A, Friedman EM, Hsu J, Husaini[...]

Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study

Freaney PM, Huang X, Petito LC, Grobman WA, Catov J, Hauspurg A, Bairey Merz CN, Bello N, Kim JK, Lane A, Haas DM, Levine LD,[...]

Prototyping and Manufacturing of Customized Over-Encapsulated Polypills for Heart Failure with Reduced Ejection Fraction in a Safety-Net Healthcare System

DeJong C, Durstenfeld MS, Davis J, Wang CS, Chen J, Kazi DS, Hickey MD, Grochowski J, Steward WT, Riley ED, Zier LS, Moreau N, Huffman[...]